Published in Drug Week, November 17th, 2006
Mutational activation of RAS occurs in about 30% of all human tumors, including non-small cell lung, pancreatic, and colon cancer. XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which is activated in 60% of melanomas, 24-44% of thyroid cancers, and 9% of colon cancers.
"XL281 emerged from our strategy to advance novel compounds that potently and selectively inhibit mutationally activated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week